小分子抗血管生成药物在非小细胞肺癌中的研究进展

肺癌的发病率和死亡率均是全球恶性肿瘤之最，目前对于晚期非小细胞肺癌的主要治疗方法有化疗、靶向治疗、免疫治疗、抗血管生成治疗及放疗。新生血管形成不仅可以促进肿瘤生长，还可协助转移、侵袭，因此目前抗血管生成药物治疗成为晚期肺癌的研究热点。VEGFR是诱导血管形成的关键因子，在包括肺癌的多种肿瘤中过度表达，抑制VEGFR不仅可以使肿瘤血管正常化还可以抑制新生血管形成，从而更好的发挥作用。VEGF抑制剂包括:抗VEGF抗体，可溶性VEGFR，抗VEGF受体抗体，小分子酪氨酸激酶抑制剂（TKIs）。目前主要用于晚期非小细胞肺癌研究的小分子药物有安罗替尼、阿帕替尼、呋喹替尼、尼达尼布、法米替尼，而且有研究表明抗血管生成药物与化疗、靶向药物、免疫抑制剂等药物联用可以增强治疗效果。因此本文主要对抗血管生成药物的作用机制，与其他药物联用的理论基础及小分子抗血管生成药物在晚期非小细胞肺癌中的研究进展进行综述。

Research progress of small molecule anti-angiogenic drugs in non-small cell lung cancer

The morbidity and mortality of lung cancer is the world's most of malignant tumor.Currently the main therapies for advanced non-small cell lung cancer methods have chemotherapy treatment，targeted treatment,immunotherapy treatment,anti-angiogenesis therapy and radiotherapy treatment.New blood vessels not only can promote the growth of tumor formation,but also to assist the transfer.Therefore,at present,anti-angiogenic drug therapy has become a research hotspot in advanced lung cancer,and VEGFR is a key factor in inducing angiogenesis.It is overexpressed in a variety of tumors including lung cancer,and inhibiting VEGFR can not only normalize tumor blood vessels,but also inhibit angiogenesis,thus playing a better role.VEGF inhibitors include anti-VEGF antibodies,soluble VEGFR,anti-VEGF receptor antibodies,small molecule tyrosine kinase inhibitors (TKIs).At present,the small-molecule drugs mainly used in the research of advanced non-small cell lung cancer include anlotinib,apatinib,furquinitinib,nidanibab and famitinib,and studies have shown that the combination of anti-angiogenic drugs with chemotherapy,targeted drugs,immunosuppressive drugs and other drugs can enhance the therapeutic effect.Therefore,this paper mainly reviews the theoretical basis of the mechanism of action of anti-angiogenic drugs in combination with other drugs and the research progress of small-molecule anti-angiogenic drugs in advanced non-small cell lung cancer.